1987
DOI: 10.1016/s0733-8619(18)30939-3
|View full text |Cite
|
Sign up to set email alerts
|

Intravenous Thyrotropin-Releasing Hormone in Patients with Amyotrophic Lateral Sclerosis: Dose-Response and Randomized Concurrent Placebo-Controlled Pilot Studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

1988
1988
2020
2020

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 30 publications
(6 citation statements)
references
References 23 publications
0
6
0
Order By: Relevance
“…The circled numbers refer to the following drugs. DM235 ( Ghelardini et al ., 2002 ); CG370 ( Ogasawara et al ., 1995 ); Cyclo (pro‐gly) ( Seredenin et al ., 2002 ); TRH ( Brooks et al ., 1987 ); ( Abou‐Khalil et al ., 2003 ; Brooks et al ., 1987 ; De Reuck & Van Vleymen, 1999 ; Devinsky & Elger, 2003 ); Piracetam ( Koskiniemi et al ., 1998 ; De Reuck & Van Vleymen, 1999 ; Genton et al ., 1999 ); Aniracetam ( Spignoli & Pepeu, 1987 ); L ‐Pyroglutamate ( Spignoli et al ., 1987 ); L060 ( Noyer et al ., 1995 ). The in vivo potencies of the drugs were obtained from literature reports of the i.p.…”
Section: Discussionmentioning
confidence: 99%
“…The circled numbers refer to the following drugs. DM235 ( Ghelardini et al ., 2002 ); CG370 ( Ogasawara et al ., 1995 ); Cyclo (pro‐gly) ( Seredenin et al ., 2002 ); TRH ( Brooks et al ., 1987 ); ( Abou‐Khalil et al ., 2003 ; Brooks et al ., 1987 ; De Reuck & Van Vleymen, 1999 ; Devinsky & Elger, 2003 ); Piracetam ( Koskiniemi et al ., 1998 ; De Reuck & Van Vleymen, 1999 ; Genton et al ., 1999 ); Aniracetam ( Spignoli & Pepeu, 1987 ); L ‐Pyroglutamate ( Spignoli et al ., 1987 ); L060 ( Noyer et al ., 1995 ). The in vivo potencies of the drugs were obtained from literature reports of the i.p.…”
Section: Discussionmentioning
confidence: 99%
“…One chronic study of intravenous administration of high dose TRH for 10 weeks demonstrated statistically significant differences compared to baseline in the increased or maintenance of strength or function in TRH -treated patients with ALS. 7 This study will have to be confirmed employing the same principles just defined in the planning of additional clinical trials of TRH or TRH analogues. Exercise capacity as fraction of baseline.…”
Section: Effect Of Chronic Intravenous Trh Treatmentmentioning
confidence: 96%
“…86 Another small parallel placebo-controlled study of intravenous administration of 10 mg/kg TRH showed significant differences between treated and placebo-treated patients in bulbar and lower extremity tests over the course of 10 weeks oftherapy. 7 Three analogues of TRH have been tested in controlled studies. 25-27.32.~No specific change was found in controlled trials of CG3509 or MK-771.…”
Section: Intravenous Administrationmentioning
confidence: 99%
“…Its synthetic analogs, i.e., Protirelin and Taltirelin hydrate, have been used to treat epilepsy, spinal cord injury, spinocerebellar ataxia, and neonatal respiratory distress (Shimizu et al, 1989;Tzeng et al, 2000;Urayama et al, 2002). Since TRH has been found in the spinal MNs, its role in the pathogenesis of MN diseases has been suggested, even if a TRH-based trial in ALS was unsuccessful (Brooks et al, 1987). However, its beneficial effects on motor functions and electromyographic results of SMA type II/III patients have been reported in different studies (small groups of infants with SMA type I in children with types II and III) and in a clinical trial (Takeuchi et al, 1994;Tzeng et al, 2000;Wadman et al, 2020).…”
Section: Hormone Signaling Pathwaysmentioning
confidence: 99%